冠心病（Coronary Artery Disease,CAD）作为全球主要的致死性疾病之一，其病理机制涉及炎症、氧化应激、脂代谢紊乱及内皮功能障碍等。鸢尾素（Irisin）是一种由运动诱导的肌肉因子，近年来被发现与心血管疾病的发生发展密切相关。近年研究发现，鸢尾素可能通过多靶点参与冠心病的病理生理过程，为心血管疾病的防治提供了新思路。本文综述了鸢尾素的生物学特性及其通过调节代谢、抑制炎症反应、改善内皮功能等途径在冠心病中的作用，并探讨其作为新型生物标志物或治疗靶点的潜在价值。

冠心病；鸢尾素；生物标志物

[1]BOSTRöM P,WU J,JEDRYCHOWSKI M P,et al.A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis[J].Nature,2012,481(7382):463-8.

[2]NIE Y,DAI B,GUO X,et al.Cleavage of FNDC5 and insights into its maturation process[J].Mol Cell Endocrinol,2020,510:110840.

[3]SCHUMACHER M A,CHINNAM N,OHASHI T,et al.The structure of irisin reveals a novel intersubunitβ-sheet fibronectin type III(FNIII)dimer:implications for receptor activation[J].J Biol Chem,2013,288(47):33738-44.

[4]HUH J Y,PANAGIOTOU G,MOUGIOS V,et al.FNDC5 and irisin in humans:I.Predictors of circulating concentrations in serum and plasma and II.mRNA expression and circulating concentrations in response to weight loss and exercise[J].Metabolism,2012,61(12):1725-38.

[5]DUN S L,LYU R M,CHEN Y H,et al.Irisin-immunoreactivity in neural and non-neural cells of the rodent[J].Neuroscience,2013,240:155-62.

[6]US ALTAY D,KEHA E E,OZER YAMAN S,et al.Investigation of the expression of irisin and some cachectic factors in mice with experimentally induced gastric cancer[J].Qjm,2016,109(12):785-90.

[7]NOWINSKA K,JABLONSKA K,PAWELCZYK K,et al.Expression of Irisin/FNDC5 in Cancer Cells and Stromal Fibroblasts of Non-small Cell Lung Cancer[J].Cancers(Basel),2019,11(10).

[8]CEBULSKI K,NOWIŃSKA K,JABLOŃSKA K,et al.Expression of Irisin/FNDC5 in Breast Cancer[J].Int J Mol Sci,2022,23(7).

[9]LI K,CHEN J,WANG C,et al.Irisin ameliorates nicotine-mediated atherosclerosis via inhibition of the PI3K pathway[J].Ann Transl Med,2021,9(9):805.

[10] ZHANG Y,SONG H,ZHANG Y,et al.Irisin Inhibits Atherosclerosis by Promoting Endothelial Proliferation Through microRNA126-5p[J].J Am Heart Assoc,2016,5(9).

[11] CHEN L,ZHAO Z W,ZENG P H,et al.Molecular mechanisms for ABCA1-mediated cholesterol efflux[J].Cell Cycle,2022,21(11):1121-39.

[12] HOU N,HAN F,SUN X.The relationship between circulating irisin levels and endothelial function in lean and obese subjects[J].Clin Endocrinol(Oxf),2015,83(3):339-43.

[13] ZHU D,ZHANG X,WANG F,et al.Irisin rescues diabetic cardiac microvascular injury via ERK1/2/Nrf2/HO-1 mediated inhibition of oxidative stress[J].Diabetes Res Clin Pract,2022,183:109170.

[14] FU J,HAN Y,WANG J,et al.Irisin Lowers Blood Pressure by Improvement of Endothelial Dysfunction via AMPK-Akt-eNOS-NO Pathway in the Spontaneously Hypertensive Rat[J].J Am Heart Assoc,2016,5(11).

[15] XIONG X Q,CHEN D,SUN H J,et al.FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity[J].Biochim Biophys Acta,2015,1852(9):1867-75.

[16] YU Q,KOU W,XU X,et al.FNDC5/Irisin inhibits pathological cardiac hypertrophy[J].Clin Sci(Lond),2019,133(5):611-27.

[17] HO M Y,WANG C Y.Role of Irisin in Myocardial Infarction,Heart Failure,and Cardiac Hypertrophy[J].Cells,2021,10(8).

[18] DENG X,HUANG W,PENG J,et al.Irisin Alleviates Advanced Glycation End Products-Induced Inflammation and Endothelial Dysfunction via Inhibiting ROS-NLRP3 Inflammasome Signaling[J].Inflammation,2018,41(1):260-75.

[19] HIRAYAMA K,ISHII H,KIKUCHI R,et al.Clinical Impact of Circulating Irisin on Classified Coronary Plaque Characteristics[J].J Appl Lab Med,2018,3(1):79-88.